Authors: | Klemen, N. D.; Kelly, C. M.; Bartlett, E. K. |
Review Title: | The emerging role of immunotherapy for the treatment of sarcoma |
Abstract: | Clinicians caring for patients with sarcoma founded the field of cancer immunotherapy. Despite this, contemporary success with immunotherapy for sarcoma has been limited. Here, we review immunotherapy for sarcoma including Coley's toxins, interleukin-2, adoptive cell transfer, and checkpoint blockade. We detail recent and ongoing efforts to combine checkpoint blockade with other immune modulators, surgery, or radiation. These results, along with ongoing investigations, have identified immunotherapeutic approaches as a promising avenue for progress in advanced sarcomas. © 2020 Wiley Periodicals LLC |
Keywords: | review; sunitinib; systemic therapy; antineoplastic agent; biological marker; animal; animals; interleukin 2; ipilimumab; ticilimumab; cancer immunotherapy; randomized controlled trials as topic; cyclophosphamide; protein tyrosine kinase inhibitor; sarcoma; immunotherapy; clinical trials, phase iii as topic; adoptive transfer; axitinib; drug therapy; clinical trials, phase i as topic; sarcomas; adoptive immunotherapy; immunotherapy, adoptive; cell transfer; interleukin-2; surgical patient; soft-tissue sarcoma; randomized controlled trial (topic); bone sarcoma; phase 3 clinical trial (topic); phase 1 clinical trial (topic); procedures; nivolumab; talimogene laherparepvec; humans; human; priority journal; checkpoint kinase inhibitor; pembrolizumab; durvalumab; immune checkpoint inhibitors; atezolizumab; checkpoint inhibition; epacadostat; bempegaldesleukin |
Journal Title: | Journal of Surgical Oncology |
Volume: | 123 |
Issue: | 3 |
ISSN: | 0022-4790 |
Publisher: | Wiley Blackwell |
Date Published: | 2021-03-01 |
Start Page: | 730 |
End Page: | 738 |
Language: | English |
DOI: | 10.1002/jso.26306 |
PUBMED: | 33259653 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | Review -- Export Date: 1 April 2021 -- Source: Scopus |